EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States

Seyed M Moghadas, Affan Shoukat, Carolyn E Bawden, Joanne M Langley, Burton H Singer, Meagan C Fitzpatrick, Alison P Galvani

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Seyed M Moghadas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Quality-Adjusted Life Years. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSERC, NSF Expeditions, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Two prefusion F protein-based vaccines, Arexvy and Abrysvo, have been authorized by the US Food and Drug Administration for protecting older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract illness. We evaluated the health benefits and cost-effectiveness of these vaccines.

Methods

We developed a discrete-event simulation model, parameterized with the burden of RSV disease including outpatient care, hospitalization, and death for adults aged 60 years or older in the United States. Taking into account the costs associated with these RSV-related outcomes, we calculated the net monetary benefit using quality-adjusted life-year (QALY) gained as a measure of effectiveness and determined the range of price-per-dose (PPD) for Arexvy and Abrysvo vaccination programs to be cost-effective from a societal perspective.

Results

Using a willingness-to-pay of $95 000 per QALY gained, we found that vaccination programs could be cost-effective for a PPD up to $127 with Arexvy and $118 with Abrysvo over the first RSV season. Achieving an influenza-like vaccination coverage of 66% for the population of older adults in the United States, the budget impact of these programs at the maximum PPD ranged from $6.48 to $6.78 billion. If the benefits of vaccination extend to a second RSV season as reported in clinical trials, we estimated a maximum PPD of $235 for Arexvy and $245 for Abrysvo, with 2-year budget impacts of $11.78 and $12.25 billion, respectively.

Conclusions

Vaccination of older adults would provide substantial direct health benefits by reducing outcomes associated with RSV-related illness in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesQuality-Adjusted Life YearsHumansUnited StatesAgedMiddle AgedViral Fusion ProteinsAged, 80 and overRespiratory Syncytial Virus, HumanMaleFemaleVaccination

Stichwörter der Autor:innen

RSVcost-effectivenessolder adultssimulationvaccination

Substanzen

Respiratory Syncytial Virus VaccinesViral Fusion Proteins

Autor:innen und Institutionen

  • Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
  • Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
  • Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
  • Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut, USA.

Förderung

  • NSERC
  • NSF Expeditions
  • NIH HHS
  • NIAID NIH HHS
  • The Notsew Orm Sands Foundation
  • NIH

Zitieren

APA

Moghadas, S. M., Shoukat, A., Bawden, C. E., Langley, J. M., Singer, B. H., Fitzpatrick, M. C., & Galvani, A. P. (2024). Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad658

Vancouver

Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, et al. Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad658

BibTeX
@article{Moghadas2024,
  author = {Moghadas, Seyed M and Shoukat, Affan and Bawden, Carolyn E and Langley, Joanne M and Singer, Burton H and Fitzpatrick, Meagan C and Galvani, Alison P},
  title = {Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad658}
}
Kostenlos starten →